RLIP76 Gene Variants are not Associated with Drug Response in Turkish Epilepsy Patients.
Approximately 30% of epileptic patients remain untreated, in spite of trials with maximum tolerable doses of more than one drug. The RalA binding protein 1 (RALBP1/RLIP76), a multifunctional, anti-apoptot-ic, multidrug transporter protein, has been proposed as being responsible for the drug resistance mechanism in epilepsy. We have investigated polymorphic differences in the coding regions and exonintron boundaries of the RLIP76 gene, between 146 refractory and 155 non refractory epileptic patients in Turkey, using denaturing high performance liquid chromatography (HPLC) and sequencing analysis techniques. We have detected the following sequence variants: c.160-4G>A, c.187C>G, c.1562-38G>A, c.1670+107G>A, c.1670+93G>A, c.1670+96G>A, c.1670+100C>T, c.1670+130C>T, c.1670+131G>C, c.1670+140 G>C, and found no statistically significant correlation between allele frequencies and drug response status. We conclude that sequence variants of this gene are not involved in drug resistance in epilepsy.
Department of Medical Biology, Faculty of Medicine, Akdeniz University, Antalya, Turkey.
E
E
Manguoğlu
S
S
Akdeniz
No
N
Dündar
O
O
Duman
B
B
Aktekin
S
S
Haspolat
U
U
Bilge
D
D
Ozel
G
G
Lüleci
Epilepsy; Neuropharmacology; Pharmacogenetics; Polymorphism; RLIP76 gene